Complete nucleotide sequences of bla(CTX-M)-harboring IncF plasmids from community-associated Escherichia coli strains in the United States

Antimicrobial Agents and Chemotherapy
Jun-Jie LiYohei Doi

Abstract

Community-associated infections due to Escherichia coli producing CTX-M-type extended-spectrum β-lactamases are increasingly recognized in the United States. The bla(CTX-M) genes are frequently carried on IncF group plasmids. In this study, bla(CTX-M-15)-harboring plasmids pCA14 (sequence type 131 [ST131]) and pCA28 (ST44) and bla(CTX-M-14)-harboring plasmid pCA08 (ST131) were sequenced and characterized. The three plasmids were closely related to other IncFII plasmids from continents outside the United States in the conserved backbone region and multiresistance regions (MRRs). Each of the bla(CTX-M-15)-carrying plasmids pCA14 and pCA28 belonged to F31:A4:B1 (FAB [FII, FIA, FIB] formula) and showed a high level of similarity (92% coverage of pCA14 and 99% to 100% nucleotide identity), suggesting a possible common origin. The blaC(TX-M-14)-carrying plasmid pCA08 belonged to F2:A2:B20 and was highly similar to pKF3-140 from China (88% coverage of pCA08 and 99% to 100% nucleotide identity). All three plasmids carried multiple antimicrobial resistance genes and modules associated with virulence and biochemical pathways, which likely confer selective advantages for their host strains. The bla(CTX-M)-carrying IncFII-IA-IB plasmids im...Continue Reading

References

Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Van CaoPatrice Courvalin
Aug 26, 2003·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Feb 23, 2008·The Lancet Infectious Diseases·Johann D D Pitout, Kevin B Laupland
Aug 30, 2008·Antimicrobial Agents and Chemotherapy·Zhiyong ZongJonathan R Iredell
Mar 25, 2009·Antimicrobial Agents and Chemotherapy·Alessandra Carattoli
Oct 12, 2010·The Journal of Antimicrobial Chemotherapy·Laura VillaAlessandra Carattoli
May 14, 2011·FEMS Microbiology Reviews·Sally R Partridge
Jan 3, 2012·The Journal of Antimicrobial Chemotherapy·Jean-Yves MadecMarisa Haenni
Nov 15, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei DoiDavid L Paterson
May 7, 2013·Nature Methods·Chen-Shan ChinJonas Korlach
Jul 16, 2013·The Journal of Antimicrobial Chemotherapy·Safia DahmenJean-Yves Madec

❮ Previous
Next ❯

Citations

May 10, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Alireza JafariHadi Sedigh Ebrahim-Saraie
Feb 13, 2018·Genome Biology and Evolution·Prabh BasraAlex Wong
Aug 15, 2019·Nature Communications·Brian M FordeScott A Beatson
Dec 16, 2020·BMC Research Notes·Rubén Monárrez, Iruka N Okeke
Dec 18, 2021·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Masahiro SuzukiYoshichika Arakawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.